August 28, 2024 01:40 PM EDT
Pharma
Law

Re­gen­eron sues San­doz to halt biosim­i­lar to its block­buster eye drug

Katherine Lewin

News Reporter

Re­gen­eron is go­ing af­ter San­doz in a New Jer­sey fed­er­al court over San­doz’s re­cent­ly-ap­proved drug En­zee­vu, a biosim­i­lar to Re­gen­eron’s block­buster eye treat­ment Eylea. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times